Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 70Breast Neoplasms 51Ovarian Neoplasms 43Lung Neoplasms 24Neoplasms 21Neoplasm Metastasis 20Fallopian Tube Neoplasms 20Carcinoma, Ovarian Epithelial 18Triple Negative Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Head and Neck Neoplasms 9Stomach Neoplasms 8Recurrence 8Endometrial Neoplasms 8Adenocarcinoma of Lung 8Melanoma 7Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 5Uterine Neoplasms 4Solid Tumors 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Adenocarcinoma, Bronchiolo-Alveolar 4Adenocarcinoma Of Esophagus 4Thoracic Neoplasms 3Testicular Neoplasms 3Solid Tumor 3Sarcoma 3

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1asparaginase erwinia chrysanthemi recombinant 1ZD4054 1Vincristine 1Paclitaxel 1Methotrexate 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Cytarabine 1Carboplatin 1Calcium Dobesilate 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Hypersensitivity × Paclitaxel × Clear all
NCT00929162 2012-08-07

ZD4054 (Zibotentan) or Placebo Plus Chemotherapy in Patients With Advanced Ovarian Cancer

AstraZeneca

Phase 2 Terminated
120 enrolled 8 charts

Hypersensitivity, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡